Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome

Trial Profile

Posttransplant Vorinostat therapy for the prevention of early relapse after allogeneic stem cell transplantation against mycosis fungoides/Sezary syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Vorinostat (Primary) ; Allogeneic stem cell therapy
  • Indications Mycosis fungoides
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Nov 2016 Status changed from recruiting to completed.
    • 20 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top